Dr. Reddy's Laboratories announced that the USFDA issued a Form 483 with two observations after a GMP inspection of its API manufacturing facility in Middleburgh, New York. The inspection, conducted between May 12-16, 2025, identified potential violations of the Food Drug and Cosmetic Act.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pfM1h8q
via...
'Irrational' fixed dose combos harmful, may face ban: Expert panel
Several personal care products containing ingredients like aloe vera, jojoba oil, and orange oil are likely to be banned in India. An expert committee has deemed these fixed-dose combinations (FDCs) as irrational and potentially harmful to human health.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ofjYH2
via IFT...
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue...
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.
from...
Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran Shaw
Biocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity, aiming to improve profitability. The company is also considering a merger with its parent company as an alternative to an IPO due to market uncertainties.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaU2g47
via...
Donald Trump’s order to lower prices may benefit generics, says Cipla CEO
Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.
from...